Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.044
Neutral
RSI(14)
52.776
Neutral
STOCH(KDJ)(9,3,3)
40.009
Buy
ATR(14)
0.131
High Vlolatility
CCI(14)
57.720
Neutral
Williams %R
65.077
Sell
TRIX(12,20)
-0.266
Sell
StochRSI(14)
46.847
Sell
Search
GlucoTrack Inc
GCTKAdd to Watchlist
0.473USD
-0.307-39.37%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.19MMarket Cap
0.07P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-39.37%
5 Days
+62.40%
1 Month
+36.01%
6 Months
-75.24%
Year to Date
-87.78%
1 Year
-92.31%
Key Figures
0.558Open
0.637High
19.77MVolume
0.07P/E TTM
--P/E Dynamic
--Dividend TTM
783.23%Turnover Ratio
0.780Prev. Close
0.419Low
7.00MTurnover
LossP/E Static
-1.40P/B
0.00%Div Yield TTM
-241.82%ROA
15.90052wk High
0.25Volume Ratio
-22.60MNet Profit
2.52MShares
6.4878EPS TTM
0.70Beta
-527.20%ROE
0.61952wk Low
27.95%Amplitude
--Gross Margin
1.19MMarket Cap
15.34Reward/Risk
9.37%Risk Rate
TradingKey Stock Score of GlucoTrack Inc
Currency: USD Updated: 2026-07-31Key Insights
GlucoTrack Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 173 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GlucoTrack Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
GlucoTrack Inc Highlights
StrengthsRisks
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is 0.07, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 221.24K shares, increasing 31.18% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
GlucoTrack Inc News
More news coming soon, stay tuned...
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.429
Buy
MA10
0.384
Buy
MA20
0.410
Buy
MA50
0.445
Buy
MA100
0.652
Sell
MA200
2.448
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
GlucoTrack Inc Info
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Ticker SymbolGCTK
CompanyGlucoTrack Inc
CEOGoode (Paul V)
Websitehttps://glucotrack.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of GlucoTrack Inc (GCTK)?
The current price of GlucoTrack Inc (GCTK) is 0.47.
What is the symbol of GlucoTrack Inc?
The ticker symbol of GlucoTrack Inc is GCTK.
What is the 52-week high of GlucoTrack Inc?
The 52-week high of GlucoTrack Inc is 15.90.
What is the 52-week low of GlucoTrack Inc?
The 52-week low of GlucoTrack Inc is 0.62.
What is the market capitalization of GlucoTrack Inc?
The market capitalization of GlucoTrack Inc is 1.19M.
What is the Earnings Per Share (EPS TTM) of GlucoTrack Inc (GCTK)?
The Earnings Per Share (EPS TTM) of GlucoTrack Inc (GCTK) is -31.22.